GB0517175D0 - Compounds - Google Patents
CompoundsInfo
- Publication number
- GB0517175D0 GB0517175D0 GBGB0517175.6A GB0517175A GB0517175D0 GB 0517175 D0 GB0517175 D0 GB 0517175D0 GB 0517175 A GB0517175 A GB 0517175A GB 0517175 D0 GB0517175 D0 GB 0517175D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- 6alkyl
- haloc1
- hydrogen
- 6alkoxy
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 150000002431 hydrogen Chemical group 0.000 abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- -1 haloC1-6alkyl Chemical group 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 102000004073 Dopamine D3 Receptors Human genes 0.000 abstract 1
- 108090000525 Dopamine D3 Receptors Proteins 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 239000000164 antipsychotic agent Substances 0.000 abstract 1
- 230000007278 cognition impairment Effects 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 206010036596 premature ejaculation Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Gynecology & Obstetrics (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0517175.6A GB0517175D0 (en) | 2005-08-22 | 2005-08-22 | Compounds |
| ES06791595T ES2320699T3 (es) | 2005-08-22 | 2006-08-18 | Derivados de azabiciclo(3.1.0)hexilfelino como moduladores de receptores d3 de dopamina. |
| US12/064,121 US7776904B2 (en) | 2005-08-22 | 2006-08-18 | Azabicyclo [3.1.0] hexylphenyl derivatives as modulators of dopamine D3 receptors |
| PCT/EP2006/008202 WO2007022935A1 (en) | 2005-08-22 | 2006-08-18 | Azabicyclo [3.1.0] hexylphenyl derivatives as modulators of dopamine d3 receptors |
| EP06791595A EP1917242B1 (en) | 2005-08-22 | 2006-08-18 | Azabicyclo [3.1.0]hexylphenyl derivatives as modulators of dopamine d3 receptors |
| DE602006004882T DE602006004882D1 (de) | 2005-08-22 | 2006-08-18 | Azabicycloä3.1.0ühexylphenylderivate als modulatoren von dopamin-d3-rezeptoren |
| JP2008527372A JP5084731B2 (ja) | 2005-08-22 | 2006-08-18 | ドーパミンd3受容体の調節因子としてのアザビシクロ[3.1.0]ヘキシルフェニル誘導体 |
| AT06791595T ATE420859T1 (de) | 2005-08-22 | 2006-08-18 | Azabicycloä3.1.0ühexylphenylderivate als modulatoren von dopamin-d3-rezeptoren |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0517175.6A GB0517175D0 (en) | 2005-08-22 | 2005-08-22 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB0517175D0 true GB0517175D0 (en) | 2005-09-28 |
Family
ID=35098086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB0517175.6A Ceased GB0517175D0 (en) | 2005-08-22 | 2005-08-22 | Compounds |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7776904B2 (https=) |
| EP (1) | EP1917242B1 (https=) |
| JP (1) | JP5084731B2 (https=) |
| AT (1) | ATE420859T1 (https=) |
| DE (1) | DE602006004882D1 (https=) |
| ES (1) | ES2320699T3 (https=) |
| GB (1) | GB0517175D0 (https=) |
| WO (1) | WO2007022935A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1745040E (pt) * | 2004-02-23 | 2010-03-08 | Glaxo Group Ltd | Derivados do azabiciclo3.1.0-hexano úteis como moduladores dos receptores d3 da dopamina |
| GB0507601D0 (en) * | 2005-04-14 | 2005-05-18 | Glaxo Group Ltd | Compounds |
| GB0507602D0 (en) * | 2005-04-14 | 2005-05-18 | Glaxo Group Ltd | Compounds |
| GB0512099D0 (en) * | 2005-06-14 | 2005-07-20 | Glaxo Group Ltd | Compounds |
| EP1891056B1 (en) * | 2005-06-14 | 2010-10-13 | Glaxo Group Limited | Novel compounds |
| EP1915146A4 (en) | 2005-07-27 | 2010-06-02 | Dov Pharmaceutical Inc | NOVEL 1-ARYL-3-AZABICYCLO [3.1.0] HEXANEES. PREPARATION AND USE FOR THE TREATMENT OF NEUROPSYCHIATRIC DISEASES |
| GB0517187D0 (en) * | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
| GB0517193D0 (en) * | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Novel use |
| US7799815B2 (en) * | 2005-08-22 | 2010-09-21 | Glaxo Group Limited | Triazole derivatives as modulators of dopamine D3 receptors |
| GB0517191D0 (en) | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
| EP2007751B1 (en) * | 2006-04-03 | 2013-08-21 | Glaxo Group Limited | Azabicyclo [3. 1. o] hexyl derivatives as modulators of dopamine d3 receptors |
| WO2007113258A1 (en) * | 2006-04-03 | 2007-10-11 | Glaxo Group Limited | Azabicyclo [3. 1. o] hexane derivatives as modulators of dopamine d3 receptors |
| KR20120106697A (ko) | 2009-06-26 | 2012-09-26 | 파나세아 바이오테크 리미티드 | 신규 아자비시클로헥산 |
| US20140206740A1 (en) | 2011-07-30 | 2014-07-24 | Neurovance, Inc. | Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters |
| MX388518B (es) | 2016-07-20 | 2025-03-19 | Novartis Ag | Derivados de aminopiridina y su uso como inhibidores selectivos de alk-2. |
| CN108997177A (zh) * | 2018-09-04 | 2018-12-14 | 邵阳学院 | 一种微波促进n-苯磺酰基硝基苯胺类化合物合成的方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL65843A (en) * | 1977-08-11 | 1986-12-31 | American Cyanamid Co | Pharmaceutical compositions for the treatment of depression containing 3-aza-bicyclo(3.1.0)hexane derivatives and certain novel compounds of this type |
| US4435419A (en) * | 1981-07-01 | 1984-03-06 | American Cyanamid Company | Method of treating depression using azabicyclohexanes |
| US6204284B1 (en) | 1991-12-20 | 2001-03-20 | American Cyanamid Company | Use of 1-(substitutedphenyl)-3-azabicyclo[3.1.0]hexanes for the treatment of chemical dependencies |
| PT1745040E (pt) | 2004-02-23 | 2010-03-08 | Glaxo Group Ltd | Derivados do azabiciclo3.1.0-hexano úteis como moduladores dos receptores d3 da dopamina |
| GB0507601D0 (en) | 2005-04-14 | 2005-05-18 | Glaxo Group Ltd | Compounds |
| GB0507602D0 (en) | 2005-04-14 | 2005-05-18 | Glaxo Group Ltd | Compounds |
| GB0507680D0 (en) | 2005-04-15 | 2005-05-25 | Glaxo Group Ltd | Compounds |
| EP1891056B1 (en) | 2005-06-14 | 2010-10-13 | Glaxo Group Limited | Novel compounds |
| JP2009502798A (ja) * | 2005-07-21 | 2009-01-29 | ワイス | 神経系障害および状態の処置方法 |
| GB0517187D0 (en) | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
| GB0517191D0 (en) | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
| GB0517193D0 (en) | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Novel use |
| US7799815B2 (en) | 2005-08-22 | 2010-09-21 | Glaxo Group Limited | Triazole derivatives as modulators of dopamine D3 receptors |
| EA200870404A1 (ru) | 2006-04-03 | 2009-04-28 | Глэксо Груп Лимитед | Производные азабицикло[3.1.0.]гексила в качестве модуляторов рецепторов допамина d3 |
| GB0616574D0 (en) | 2006-08-21 | 2006-09-27 | Glaxo Group Ltd | Compounds |
| DE102006035468A1 (de) * | 2006-11-29 | 2008-06-05 | Dilo Trading Ag | Modifizierte Elektroden für elektrische Energiespeicher |
-
2005
- 2005-08-22 GB GBGB0517175.6A patent/GB0517175D0/en not_active Ceased
-
2006
- 2006-08-18 WO PCT/EP2006/008202 patent/WO2007022935A1/en not_active Ceased
- 2006-08-18 DE DE602006004882T patent/DE602006004882D1/de active Active
- 2006-08-18 US US12/064,121 patent/US7776904B2/en not_active Expired - Fee Related
- 2006-08-18 EP EP06791595A patent/EP1917242B1/en active Active
- 2006-08-18 AT AT06791595T patent/ATE420859T1/de not_active IP Right Cessation
- 2006-08-18 JP JP2008527372A patent/JP5084731B2/ja not_active Expired - Fee Related
- 2006-08-18 ES ES06791595T patent/ES2320699T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP1917242B1 (en) | 2009-01-14 |
| US20090030062A1 (en) | 2009-01-29 |
| DE602006004882D1 (de) | 2009-03-05 |
| EP1917242A1 (en) | 2008-05-07 |
| ATE420859T1 (de) | 2009-01-15 |
| JP2009504793A (ja) | 2009-02-05 |
| ES2320699T3 (es) | 2009-05-27 |
| WO2007022935A1 (en) | 2007-03-01 |
| JP5084731B2 (ja) | 2012-11-28 |
| US7776904B2 (en) | 2010-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB0517191D0 (en) | Compounds | |
| GB0517175D0 (en) | Compounds | |
| EA201000050A1 (ru) | Замещенные бициклолактамные соединения | |
| JO2686B1 (en) | Vehicles | |
| MY146662A (en) | Novel n-(8-heteroaryltetrahydronaphtalene-2yl) or n-(5-heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain | |
| BRPI0409109A (pt) | novos compostos | |
| PT1716152E (pt) | Compostos heterocíclicos fundidos e sua utilização como antagonistas do receptor metabotrópico para o tratamento de distúrbios gastrointestinais | |
| WO2009069032A3 (en) | Novel glucocorticoid receptor agonists | |
| EA200700099A1 (ru) | Производные пиридина | |
| MX2009011816A (es) | Derivados de piridina. | |
| MY143581A (en) | Carboxamide derivatives as muscarinic receptor antagonists | |
| EA200702200A1 (ru) | Дигидротиенопиримидины для лечения воспалительных заболеваний | |
| MY145613A (en) | Novel compounds | |
| EA200801011A1 (ru) | Производные пиразина как модуляторы натриевых каналов для лечения боли | |
| MX2010002938A (es) | Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer. | |
| PH12012501863A1 (en) | 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators | |
| MX2011012669A (es) | Nuevos agonistas del receptor de glucocorticoides. | |
| MY158069A (en) | Tricyclic compound and pharmaceutical use thereof | |
| TW200745122A (en) | New compounds I | |
| TW200639156A (en) | New compounds | |
| GB0507601D0 (en) | Compounds | |
| DK1648904T3 (da) | N-sulfonylheterocyclopyrrolalkylaminforbindelser som 5-hydroxytryptamin-6-ligander | |
| MX2009013775A (es) | Sustituto novedoso de piperidones sustituidas como inductor de hsp. | |
| MX2007003119A (es) | Nuevas amidas heterociclicas. | |
| TW200730512A (en) | Novel compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |